President Donald Trump promised lower healthcare costs, and he's bringing lower healthcare costs.

This week, Trump announced more voluntary deals with drug manufacturers under which they agreed to cut their U.S. prices to the rates they charge in other countries.

This was a textbook example of free-market healthcare policy in action. Mandates weren’t needed: these CEOs had every reason to ensure they do not lose out on the business the federal government provides.

This week’s agreements bring the total number of price reduction deals struck by the Trump administration with drug manufacturers to 26, covering 89 percent of the branded drug market. The Council of Economic Advisers puts the projected savings from these deals at $600 billion over the next decade.

The Trump administration is clearly proving effective at cutting drug costs. Now, it should apply the same free-market treatment to other areas of the healthcare market.

Cut the approval timelines that drive up drug prices

Remember Martin Shkreli, the “Pharma Bro” who bought the rights to a drug called Daraprim and raised the price overnight to $750 a pill? The resulting outrage was aimed at Shkreli, but the real story was........

© Townhall